US OptionsDetailed Quotes

OCUL250516P5000

Watchlist

0.05
0.000.00%

15min DelayClose May 6 16:00 ET

0.00High0.00Low

Ocular Therapeutix Stock Discussion

Teddy123

May 5 19:11

Ocular Therapeutix™ Reports First Quarter 2025 Results and Business Highlights

$Ocular Therapeutix (OCUL.US)$
Ocular Therapeutix Earnings: $349M War Chest Powers AXPAXLI Trials as FDA Backs NPDR Program

Jerry Kronenberg

Mar 4 05:30

Columns Wall Street Today: Nasdaq Sheds 2%+, S&P 500 and DJIA Sink as Trump Confirms Canadian and Mexican Tariffs

Stocks tumbled Monday after President Trump confirmed plans to impose tariffs on Mexican and Canadian imports, sending the Nasdaq Composite down nearly 3% and the Dow industrials and S&P 500 off by some 1.5%.
The $Nasdaq Composite Index (.IXIC.US)$ shed 497.09 points (2.6%) to an 18,350.19 close, while the $S&P 500 Index (.SPX.US)$ sank 104.78 ticks (1.8%) to 5,849.72. The $Dow Jones Industrial Average (.DJI.US)$ likewise ...

Hot tech stocks pull back into the storm, a good opportunity to bottom or a risky trap?

Jerry Kronenberg

Mar 4 05:06

Columns Nasdaq Sheds 2%+, S&P 500 and DJIA Sink Some 1.5% as Trump Confirms Canadian and Mexican Tariffs

Stocks tumbled Monday after President Trump confirmed plans to impose tariffs on Mexican and Canadian imports, sending the Nasdaq Composite down nearly 3% and the Dow industrials and S&P 500 off by some 1.5%.
The $Nasdaq Composite Index (.IXIC.US)$ shed 497.09 points (2,6%) to a 18,350.19 close, while the $S&P 500 Index (.SPX.US)$ sank 104.78 ticks (1.8%) to 5,849.72. The $Dow Jones Industrial Average (.DJI.US)$ likewise ...

Hot tech stocks pull back into the storm, a good opportunity to bottom or a risky trap?

Teddy123

Mar 3 20:07

Ocular Therapeutix™ Reports Fourth Quarter and Full Year 2024 Results and Business Highlights

$Ocular Therapeutix (OCUL.US)$
Can Ocular Therapeutix's $392M Cash Position Fuel Its AMD Treatment Through Approval?

Trytosaveabit

Aug 7, 2024 19:11

Update

$Ocular Therapeutix (OCUL.US)$ Ocular Therapeutix Has Received FDA Written Response That Phase 3 Sol-r Trial Is Appropriate For Use As The Company's Second Adequate And Well Controlled Study Of Axpaxli (Axitinib Intravitreal Implant, Also Known As OTX-TKI) For Wet Age-related Macular Degeneration